Trials / Completed
CompletedNCT01163396
First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer
Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Gruppo Oncologico del Nord-Ovest · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multicentre phase II study evaluating the safety and efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line treatment of metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | |
| DRUG | Irinotecan | |
| DRUG | Oxaliplatin | |
| DRUG | 5-fluorouracil/leucovorin |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-04-01
- Completion
- 2010-04-01
- First posted
- 2010-07-15
- Last updated
- 2015-03-11
Source: ClinicalTrials.gov record NCT01163396. Inclusion in this directory is not an endorsement.